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tory failure. CTPA was done to rule out pulmonary embolism, which showed
no pulmonary embolism but bilateral gross consolidation, more on the right,
in keeping with an infective process. Antibiotics were changed to intrave-
nous Ceftriaxone and Azithromycin; however, there was continuous deterio-
ration and patient succumbed to his illness on day 4 of admission. His throat
swab was later traced back to be positive for MERS-CoV, while his sputum
was negative for bacterial cultures.PS 2-334
INFLUENZA A (H1N1) PNEUMONIA WITH ACUTE RESPIRATORY DISTRESS
SYNDROME (ARDS) AND RHABDOMYOLYSIS WITH ACUTE RENAL FAILURE:
A CASE REPORT
Mei-Chen Chen a, Wen-Liang Yu b, Chin-Ming Chen c. aDepartment of
Nursing, Chi Mei Medical Center, Yong Kang, Tainan City, Taiwan;
bDepartment of Intensive Care Medicine, Chi-Mei Medical Center, Tainan,
Taiwan; cDepartment of Intensive Care Medicine, Chi-Mei Medical Center,
Tainan, Taiwan
Purpose: It is generally noted that patients with pneumonia from pandemic
H1N1 may have abnormal laboratory examination results, including elevated
creatine kinase (CK) levels in the previous literatures. We herein report a
similar case complicated with ARDS and rhabdomyolysis.
Case report
This 36-year-old woman was admitted to our emergent room with fever for 2
days. She was transferred to the ICU due to influenza A pneumonia with ARDS
and profound hypoxemia. Immediate endotracheal intubation was done and
Nitrogen oxide (NO) was used for profound hypoxemia. Prone position
ventilation was not attempted due to morbid obesity. Antibiotic therapy
with Tazozin, Cravit and Tamiflu was used. Dopamine was prescribed due to
refractory shock post resuscitation. However, no significant bacterial culture
result was obtained, except a positive PCR for Influenza A (H1N1). The PaO2/
FiO2 ratio remained < 200 mmHg, requiring the use of high PEEP, fully
sedation and muscle relaxant to maintain the oxygenation. However, fever
and shock persisted, hence, Cravit was shifted to Tygacil. The subsequent
follow-up blood culture was negative. Poor oxygenation hindered her from the
study of Computed Tomography. Oliguria with tea-colored urine was noted.
Marked elevation of CK total [7601 IU/L] and myoglobin [32890 mg/dL] were
noted. Rhabdomyolysis with acute renal failure was impressed, which was
probably related to H1N1 infection. After the treatment, the condition was
still worsening. Due to unstable blood pressure and severe metabolic acidosis
with oliguria, continuous veno-veno hemofiltration (CVVH) was commenced.
Then the patient finally expired due to progressive condition.
Conclusions: Although pneumonia and ARDS are the most common severe
complications of H1N1 infection. Rhabdomyolysis should be considered in
the evaluation of muscle symptoms associated with Influenza A (H1N1) Pneu-
monia, especially in critically ill patients. Timely extra-corporeal membrane
oxygenation may be helpful to survive the patients with life-threatening
Influenza infection.PS 2-335
URINARY TRACT INFECTION CAUSED BY MYROIDES SPECIES: A CASE
REPORT
Mei-Yu Su a, Wen-Liang Yu a,b, Che-Kim Tan a. aDepartment of Intensive
Care Medicine, Taiwan; bChi-Mei Medical Center, Tainan City, Taiwan
Purpose: Myroides species are widely distributed in nature, but clinical hu-
man infections by these organisms are extremely rare. We report herein pro-
longed outbreak of urinary tract infection by Myroides species.
Case report
A 63-year-old male of end stage renal disease, rheumatoid arthritis,
destroyed lung post operation, post tracheostomy suffered from conscious-
ness change and much sputum for five days. He was brought to emergency
department on November 17, 2014. Laboratory data shows leukocytosis
(WBC: 13,300/mL); bandemia (band: 5%); and C-reactive protein, 113 mg/
L. CXR showed almost whiteout of the right side destroyed lung with residual
alveolar, surgical clips and suture stitches left. Ceftazidime was given. Brain
CT showed mild communicating hydrocephalus and mixed acute and old
lacunar infarcts. He was admitted to intensive care unit (ICU). Emergent
ventilator support was used due to dyspnea and respiratory failure. Feverhappened. Sputum culture showed Pseudomonas aeruginosa and carbape-
nem-resistant Acinetobacter baumannii. Urine culture showed Myroides
species, susceptible to imipenem and piperacillin/tazobactum, but resistant
to ceftazidime and ciprofloxacin. Antibiotic was shifted to ceftazidime and
colistin. The patient condition improved gradually under medical treatment
and started weaning trial, but ABG showed CO2 retention. Owing to ventila-
tion dependence and improved condition, he was transferred to the RCW for
long-term care on November 27, 2014.
Conclusion
Serious and prolonged nosocomial outbreaks of urinary tract infections
caused by M. odoratimimus have been reported. Because multiresistance
was generally found in Myroides spp., empirical therapy was usually ineffec-
tive. We report a nosocomial urinary tract infection by Myroides spp.PS 2-336
BETADINE SOLUTION, BETADINE SKIN CLEANSER, BETADINE
SURGICAL SCRUB, AND BETASEPTIC DEMONSTRATED EXCELLENT
VIRUCIDAL IN-VITRO EFFICACY AGAINST EBOLA VIRUS ZAIRE AND
MODIFIED VACCINIA VIRUS ANKARA
Maren Eggers a, Markus Eickmann b, Juergen Zorn c. aLabor Prof. Gisela
Enders MVZ GbR, Stuttgart, Germany; bInstitute for Virology, Philipps
University of Marburg, Marburg, Germany; cMundipharma Research GmbH &
Co.KG, Limburg, Germany
Purpose: The current Ebola virus (EBOV) epidemic highlights the need for
efficacious virucidal products. In Europe, EN 14476:2013/A1:2014 describes
the standard for determining virucidal activity. For the claim ‘virucidal
active against enveloped viruses for hygienic handrub and handwash’ the
Modified vaccinia virus Ankara (MVA) was introduced as reference virus in
2014. In the case of deadly EBOV, which is also an enveloped virus, the ac-
tivity needs to be proven.
The first aim of this study was to test the in-vitro efficacy of four povidone
iodine (PVPI) formulations containing 4% (BETADINE Skin Cleanser), 7.5%
(BETADINE Surgical Scrub), 10% (BETADINE Solution) PVPI and 3.2% PVPI
and 78% alcohol (BETASEPTIC). The second aim was to verify the claimed
concentration-contact-time values with EBOV.
Methods: In accordance with EN 14476 a standard suspension test was used
for testing against MVA and large-volume plating technology for testing
against EBOV to increase test sensitivity and to exclude potential after-ef-
fects. All products were tested under clean (0.3 g/l BSA) and dirty conditions
(3.0 g/l BSA + 3.0 ml/l erythrocytes) as interfering substance with an appli-
cation time of 15, 30, and 60 seconds for MVA and 15 seconds for EBOV. The
products were tested undiluted, 1:10 and 1:100 diluted against MVA and 1:10
diluted against EBOV.
Results: Viral titres of MVA and EBOV were reduced by >99.99% to >99.999%
under clean and dirty conditions with 15 seconds application.
Conclusions: All products showed excellent virucidal efficacy against EBOV
demonstrating the important role PVPI can play in the prevention and
limiting the spread of the Ebola disease. The proven efficacy against both
test viruses with 15 seconds application time is helpful information for
implementation of appropriate guidance to people exposed to EBOV and
confirms excellent virucidal efficacy of PVPI against enveloped viruses.
Sponsored by Mundipharma Research
: BETADINE and BETASEPTIC are Registered TrademarksPS 2-337
CYTOMEGALOVIRUS VIREMIA IN PATIENTS WHO WERE INFECTED WITH
HUMAN IMMUNODEFICIENCY VIRUS
Lin Chai Yi, Shu-Hsing Cheng, Pai-Ling Chang. Department of Laboratory
Medicine & Department of Infection Diseases TaoYuan General Hospital,
Ministry of Health and Welfare, Taiwan
Introduction: At the end of 2014, there were more than 28,000 reported
HIV-infected patients in Taiwan. Cytomegalovirus (CMV) infection, second-
ary to Pneumocystis jeroveci pneumonia and candidiasis, is the 3rd common
opportunistic infections in HIV-infected persons. This study aimed to explore
the relationships between CMV DNA quantitation and the severity of immune
compromised states among HIV patients.
Methods: Real time polymerase chain reaction (RT-PCR) was applied to
detect CMV DNA using COBAS AmpliPrep/COBAS TaqMan CMV assay (Roche
S134 Abstracts of the 7th International Congress of the Asia Pacific Society of Infection Control, Taipei, Taiwan, March 26-29, 2015Diagnotics, Indianapolis, IN, USA). The correlations with HIV viral loads and
CD4+ T-cell counts were further analyzed.
Results: Totally 291 HIV-infected cases were enrolled. Their mean ages
were 35.9 (standard deviation; 9.4) years, male：female ratio；254
(87.3%)：37(12.7%). Among them, 98.8% (168/170) showed CMV IgG posi-
tivity. Ninety-five patients (32.6%) had CD4+T cell count >Z500 cells/
uL; 156 patients (53.6%), >Z200 - <500cells/uL; and 40 patients
(13.7%), <200cells/uL. In addition, 23 (7.9%) patients had HIV viral load
>Z100,000 copies/ml; 98 patients (33.7%), >Z400 - <100,000; 50 pa-
tients (17.1%), >Z20 - <400; and 120 patients (41.2%), < 20 copies/ml.
Among them, 268 cases (92.1%) had negative CMV DNA detection, 16 cases
(5.5%) had detectable CMV DNA (<150 copies/mL), and 7 cases (2.4%) had
CMV DNA>150 copies/ml. Patients who had CD4+ T cell counts<200 cells/
uL have 5 times of odds ratio to develop CMV viremia, compared to sub-
jects who have CD4+ T cell counts > 500 cells/uL. Patients who had
HIV viral load >100,000 copies/ml have 129 times of odds ratio to develop
CMV viremia, compared to subjects who have HIV viral load <20
copies/ml.
Conclusion: Early initiation of highly active antiretroviral therapy would
prompt the recovery of immune deficiency, and certainly alleviate the
burden of CMV viremia.Table Demographic Features and Treatment Outcome
Characteristics MSM (NZ43) IDU and others (NZ11) P value
Age (years)PS 2-338
CLINICAL EXPERIENCES IN INTERPRETATION OF HIV-1 WESTERN BLOT
INDETERMINATE RESULTS
Kuo-Chen Weng a, Shu-Yuan Ho a, Sui-Yuan Chang a,b. aDepartments of
Laboratory Medicine, National Taiwan University Hospital, Taiwan;
bDepartment of Clinical Laboratory Sciences and Medical Biotechnology,
National Taiwan University, Taiwan
Purpose: According to the guidelines published by Taiwan Centers for Dis-
ease Control, status of HIV infection has to be confirmed by a positive West-
ern blot (WB) results after the HIV-1/2 antibody screening assay. However,
the interpretation of WB results might vary according to the package inserts
of the commercial manufacturers, which might cause disagreement between
different clinical laboratories.
Methods: The clinical outcomes of 1712 patients whose specimens were sent
for HIV WB tests between May 2006 and April 2012 were analyzed. The BIO-
RAD NEW LAV BLOT I, II was used by the Virology laboratory of the National
Taiwan University Hospital.
Results: Between the study period, a total of 1712 HIV WB-I tests were per-
formed, which include 1015 positive, 285 indeterminate, and 412 negative
results. For those who are determined as HIV WB-I positive, they are sero-
positive for GP160 (NZ1,014), GP110/120 (NZ995), P68/66 (NZ973), P55
(NZ885), P52/51 (NZ941), GP41 (NZ945), P40 (NZ602), P34/31
(NZ902), P24/25 (NZ937), and P18/17 (NZ679). For the indeterminate
HIV WB-I, four patterns are most common and they are P24/25 (NZ46),
P18/17 (NZ26), GP160 + P55 + P24/25 (NZ22), and P55 (NZ22). Among
the 22 patients reactive with GP160 + P55 + P24/25, 20(91%) are confirmed
with HIV infection status and two were lost of follow-up.
For HIV WB-II, among the 228 tests, none was positive. 98 are indeterminate
and 130 are negative. Most of the indeterminate HIV WB-II are sero-positive
with P26(NZ57). None of them are confirmed with HIV-2 infection at the end
of the study period.
Conclusions: Based on the study results, for those who have indeterminate
WB results, two or more interpretation criteria are suggested to help inter-
pretation, such WHO CRITERIA: 2ENV  GAG  POL and US CENTER FOR DIS-
EASE CONTROL CRITERIA: ENV + P24 / 25.Median [IQR] 34 (30e40) 43 (41e51) .011
Ongoing ART
Any 41 (95.3%) 5 (45.5%) < .001
Last HIV-1 RNA (copies/mL)
<40 32/40 (80.0%) 4/11 (36.4%) .009
HCV Genotype
GT1 11/31 (35.5%) 7/10 (70.0%) .075
GT2 18/31 (58.1%) 2/10 (20.0%) .067
GT6 0/31 (0.0%) 1/10 (10.0%) .244
Treatment Outcome
RVR 17/26 (65.4%) 3/6 (50.0%) .647PS 2-339
HIV-1 CRF08_BC MUTANTS RESISTANT TO REVERSE TRANSCRIPTASE
INHIBITORS
Hao Wu, Xiao-Min Zhang, Bo-Jian Zheng. Department of Microbiology, The
University of Hong Kong, Hong Kong
Purpose: Human immunodeficiency virus type (HIV)-1 circulating recombi-
nant form 08_BC (CRF08_BC), carrying recombinant reverse transcriptase
(RT) gene from subtype B and C, has recently become highly prevalent in
Southern China. As the number of patients infected by CRF08_BC increases,it is important to characterize the drug resistance mutations of CRF08_BC,
especially against widely used antiretrovirals.
Methods: In this study, clinically isolated virus was propagated in human pe-
ripheral blood mononuclear cells (PBMCs) with increasing concentrations of
nevirapine (NVP), efavirenz (EFV) or lamivudine (3TC).
Results: Three different resistance patterns led by initial mutations of
Y181C, E138G and Y188C were detected after in vitro selection with NVP. Vi-
rus variants with initial mutations, in combination with three other previ-
ously reported substitutions (K20R, D67N, V90I, K101R/E, V106I/A, V108I,
F116L, E138R, A139V, V189I, G190A, D218E, E203K, H221Y, F227L, N348I
and T369I) or novel mutations (V8I, S134N, C162Y, L228I, Y232H, E396G
and D404N) developed during NVP selection. EFV-associated variations con-
tained two initial mutations (L100I and Y188C) and three other mutations
(V106L, F116Y and T139V). Phenotypic analyses showed that E138R, Y181C
and G190A contributed high level resistance to NVP, while L100I and V106L
significantly reduce virus susceptibility to EFV. Y188C resulted in a 20-fold
reduction of susceptibility to both NVP and EFV. M184V was selected by
3TC as expected. This mutation, alone or with V90I or D67N, decreased
3TC susceptibility by over 1000 folds.
Conclusion: These results have brought new insight into the development of
drug-related mutations in patients and provided useful information for the
optimization of antiretroviral regimens.PS 2-340
PEGYLATED INTERFERON/RIBAVIRIN TREATMENT HIGHLY EFFECTIVE IN
HIV/HCV-COINFECTED MEN WHO HAVE SEX WITH MEN IN TAIWAN: SINGLE
MEDICAL CENTER EXPERIENCE
Wen-wei Ku a, Yea-yuan Chang b, Chih-hao Chang c, Bor-shen Hu d, Wong-
wing Wai b. aDivision of Infectious Diseases, Taipei Veterans General Hospital,
Hsinchu Branch, Hsinchu, Taiwan; bDivision of Infectious Diseases, Taipei
Veterans General Hospital, Taipei, Taiwan; cDivision of Gastroenterology,
Taipei Veterans General Hospital, Taipei, Taiwan; dDivision of Infectious
Diseases, Taipei City Hospital, Heping Branch, Taipei, Taiwan
Purpose: A recent outbreak of HCV infection has been identified among HIV-
infected men who have sex with men (MSM) worldwide, including Taiwan
since 2006. Pegylated interferon (PEG-IFN) with ribavirin (RBV) remains stan-
dard of treatment in most Asian countries. However, very few studies have
evaluated the treatment efficacy in such particular population.
Methods: We conducted a single-centered, retrospective cohort study of
HIV-1 infected patients in Northern Taiwan from 2006 to 2014. Persistent
HCV infection was diagnosed with positive anti-HCV serology and a detect-
able HCV viral load. Clinical characteristics, HIV-1 infection status, use of
antiretroviral therapy (ART), HCV genotypes, and IL-28B genotypes were
collected at baseline, during PEG-IFN plus RBV treatment, and at follow-up.
Results: Fifty-four patients had persistent HCV infection, of whom 43 were
MSM. They were significantly younger and received ART with an undetectable
HIV-1 viremia more often than the other cohort (Table). Thirty-four MSM were
eligible for treatment and had a very high sustained virological response (SVR)
rate regardless of HCV genotypes (80.0% [4/5] for GT 1, 100.0% [7/7] for non-
GT 1, p Z .417). Skin manifestations (local injection reaction and alopecia),
anemia, and depression were the most frequent adverse effects.EVR 21/21 (100.0%) 5/5 (100.0%) NA
SVR 18/19 (94.7%) 0/1 (0.0%) .100
